Identification of patients at high risk of secondary extramedullary multiple myeloma development
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F22%3A10434500" target="_blank" >RIV/00669806:_____/22:10434500 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/22:E0109456 RIV/65269705:_____/22:00075995 RIV/00064173:_____/22:43922541 RIV/00098892:_____/22:10157299 and 7 more
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=exWLn5lRgT" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=exWLn5lRgT</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/bjh.17925" target="_blank" >10.1111/bjh.17925</a>
Alternative languages
Result language
angličtina
Original language name
Identification of patients at high risk of secondary extramedullary multiple myeloma development
Original language description
Multiple myeloma (MM) is characterized by malignant plasma cell infiltration of the bone marrow. In extramedullary multiple myeloma (EMD), a subclone of these cells migrates out of the bone marrow. Out of 4 985 MM patients diagnosed between 2005 and 2017 in the Czech Republic, we analyzed 234 secondary EMD patients to clarify risk factors of secondary EMD development. We found younger age [<65 years; odds ratio (OR) 4 center dot 38, 95% confidence interval (CI): 2 center dot 46-7 center dot 80, P < 0 center dot 0001], high lactate dehydrogenase (LDH) levels (>5 mu kat/l; OR 2 center dot 07, 95% CI: 1 center dot 51-2 center dot 84, P < 0 center dot 0001), extensive osteolytic activity (OR 2 center dot 21, 95% CI: 1 center dot 54-3 center dot 15, P < 0 center dot 001), and immunoglobulin A (IgA; OR 1 center dot 53, 95% CI: 1 center dot 11-2 center dot 11, P = 0 center dot 009) or the non-secretory type of MM (OR 2 center dot 83; 95% CI: 1 center dot 32-6 center dot 04, P = 0 center dot 007) at the time of MM diagnosis to be the main risk factors for secondary EMD development. Newly diagnosed MM (NDMM) patients with subsequent EMD had inferior median progression-free (PFS) and overall (OS) survival when compared to NDMM patients without future EMD [mPFS: 13 center dot 8 months (95% CI: 11 center dot 4-16 center dot 3) vs 18 center dot 8 months (95% CI: 17 center dot 7-19 center dot 9), P = 0 center dot 006; mOS: 26 center dot 7 months (95% CI: 18 center dot 1-35 center dot 4) vs 58 center dot 7 months (95% CI: 54 center dot 8-62 center dot 6), P < 0 center dot 001]. We found that NDMM patients with specific risk factors associated with secondary EMD development have a more aggressive disease course before secondary EMD develops.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
<a href="/en/project/NV17-29343A" target="_blank" >NV17-29343A: Bone marrow microenvironment analysis in extramedullary relapse of multiple myeloma</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
British Journal of Haematology
ISSN
0007-1048
e-ISSN
1365-2141
Volume of the periodical
196
Issue of the periodical within the volume
4
Country of publishing house
GB - UNITED KINGDOM
Number of pages
9
Pages from-to
954-962
UT code for WoS article
000713664200001
EID of the result in the Scopus database
2-s2.0-85118348754